Cargando…
Leflunomide-induced pulmonary arterial hypertension in a young man with nephrotic syndrome: A case report
Drug-induced pulmonary arterial hypertension (PAH) has been widely reported but PAH caused by leflunomide is very rare. Here we report the case of a young man with nephrotic syndrome treated with leflunomide for 5 years before being admitted to our hospital for dyspnea. After discontinuing leflunomi...
Autores principales: | Luo, Xiaoqin, Li, Jiang, Chen, Sisi, Luo, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623250/ https://www.ncbi.nlm.nih.gov/pubmed/36330099 http://dx.doi.org/10.3389/fphar.2022.992457 |
Ejemplares similares
-
Evaluating the role of serum uric acid in the risk stratification and therapeutic response of patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD)
por: Luo, Jun, et al.
Publicado: (2023) -
Efficacy and Safety of Leflunomide for Refractory COVID-19: A Pilot Study
por: Wang, Qiang, et al.
Publicado: (2021) -
The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study
por: Chen, Yusi, et al.
Publicado: (2022) -
Corrigendum: The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-Word Prospective Study
por: Chen, Yusi, et al.
Publicado: (2022) -
Magnolol Attenuates Right Ventricular Hypertrophy and Fibrosis in Hypoxia-Induced Pulmonary Arterial Hypertensive Rats Through Inhibition of the JAK2/STAT3 Signaling Pathway
por: Fu, Minyi, et al.
Publicado: (2021)